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ABSTRACT
In 2019, 12 topics were selected as the major research advances in gynecologic oncology. 
Herein, we first opted to introduce the significant clinical activity of pembrolizumab in 
women with advanced cervical cancer based on the results of the phase 2 KEYNOTE-158 
trial. Thereafter, we reviewed 5 topics, including systemic lymphadenectomy in the advanced 
stage with no gross residual tumor, secondary cytoreductive surgery in recurrent ovarian 
cancer according to the results of Gynecologic Oncology Group-213 trial, dose-dense weekly 
paclitaxel scheduling as first-line chemotherapy, the utility of intraperitoneal therapy in 
the advanced stage, and an update on poly(ADP-ribose) polymerase (PARP) inhibitors for 
the treatment of ovarian cancer. Additionally, we conducted a thorough review of emerging 
data from several clinical trials on PARP inhibitors according to drug, target population, 
and combined usage. For uterine corpus cancer, we reviewed adjuvant therapy for high-risk 
disease and chemotherapy in advanced/recurrent disease. For the field of radiation oncology, 
we discussed the utility of neoadjuvant chemotherapy added to chemoradiotherapy and the 
treatment of radiation-induced cystitis using hyperbaric oxygen. Finally, we discussed the use 
of individualized therapy with humanized monoclonal antibodies (trastuzumab emtansine 
and sacituzumab govitecan-hziy) and combination therapy (fulvestrant plus alpesilib, 
fulvestrant plus anastrozole, and ribociclib plus endocrine therapy) for women with advanced 
breast cancer.
Keywords: Immunotherapy; Poly(ADP-ribose) Polymerase Inhibitors; Adjuvant Therapy; 
Humanized Monoclonal Antibody; Combination Therapy
INTRODUCTION
Among the 12 topics presented herein regarding the major clinical research advances in 2019, 
we opted to specifically present an update on Poly(ADP-ribose) polymerase (PARP) inhibitors. 
Following the publication of the findings of the SOLO-1 trial (NCT01844986) in the New 
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England Journal of Medicine [1], PARP inhibitors beyond olaparib were actively evaluated in 
women with ovarian cancer in different clinical settings. In the Platelet-Rich plasma Injection 
Management for Ankle OA (PRIMA) trial, patients with newly diagnosed advanced ovarian 
cancer that responded to platinum-based chemotherapy had significantly longer progression-
free survival (PFS) with PARP inhibitors than those administered the placebo, regardless of 
homologous-recombination deficiency or proficiency [2]. As patients were enrolled despite 
their biomarker status or the time of surgery in the Veliparib With Carboplatin and Paclitaxel 
and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, 
High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (VELIA) 
trial (NCT02470585), the benefit of PARP inhibitors can be safely extended to all patients 
with newly diagnosed advanced ovarian cancer [3].
In this review, we summarized the remarkable findings of studies on PARP inhibitors. The 
12 topics related to the major clinical research advances in gynecologic cancer in 2019 are 
presented in Table 1.
UTERINE CERVIX
1. Immunotherapy
The results of the KEYNOTE-158 basket trial were first reported at the 2018 American Society 
of Clinical Oncology (ASCO) Annual Meeting. These findings led to the approval of the 
single-agent, pembrolizumab, for the treatment of women with recurrent or metastatic 
cervical cancer expressing programmed death-ligand 1 (PD-L1; combined positive score 
[CPS] ≥1) by the U.S. Food and Drug Administration.
In 2019, pembrolizumab was found to display notable clinical activity in women with 
previously treated advanced cervical cancer in the phase 2 KEYNOTE-158 trial [4]. A total of 
98 previously treated women with advanced cervical cancer received 200 mg pembrolizumab 
3 times per week for 2 years or experienced disease progression or intolerable toxicity. Most 
patients (83.7%) had PD-L1-positive tumors based on a CPS value ≥1. The overall response 
rate of the study population was 12.2%, with a median follow-up of 10.2 months: 3 complete 
responses and 9 partial responses. All 12 women with objective responses had PD-L1-positive 
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Table 1. Twelve topics related to the major clinical research advances in gynecologic cancer in 2019
Site of cancer Topic Reference
Uterine cervix Immunotherapy [1]
Ovary Systemic lymphadenectomy in advanced ovarian cancer [2]
Secondary cytoreductive surgery in recurrent ovarian cancer [4]
Dose-dense weekly paclitaxel scheduling [9]
Intraperitoneal therapy [13]
PARP inhibitor update [18-26, 28-30]
Uterine corpus Adjuvant therapy for high-risk endometrial cancer: GOG-258 and 
GOG-249
[35,36]
Chemotherapy for high-risk endometrial cancer: JGOG-2043 and 
GOG-261
[38,39]
Radiation oncology Inferiority of NAC plus CRT to CRT alone [40]
Treatment of radiation-induced cystitis with hyperbaric oxygen [42]
Breast Humanized monoclonal antibodies in breast cancer [43,44]
Combination therapy in breast cancer [45,47,51]
CRT, chemoradiotherapy; GOG, Gynecologic Oncology Group; NAC, neoadjuvant chemotherapy; PARP, poly (ADP-
ribose) polymerase.
tumors. Women with PD-L1-positive tumors had a longer median overall survival (OS) than 
those with PD-L1-negative tumors (11 months vs. 9.4 months).
Adverse events of any grade were found in 65.3% of cases, and grade 3 or higher adverse 
events were found in 12.2% of participants. Approximately one-quarter of participants 
experienced immune-mediated adverse events: 2 hepatitis, 2 severe skin reactions, and 1 
adrenal insufficiency.
OVARY
1. Systemic lymphadenectomy in advanced ovarian cancer
The lymph node is involved in as many as 80% of cases of women with ovarian cancer [5]. 
Although systematic lymphadenectomy is a feasible and safe procedure for advanced ovarian 
cancer, its therapeutic role remains controversial. Retrospective studies have suggested 
significant survival benefits of systematic lymphadenectomy in women with primary 
cytoreductive surgery for the advanced stage. However, in 2005, Panici et al. [6] suggested 
that systematic lymphadenectomy improves PFS but not OS in women with advanced ovarian 
carcinoma optimally debulked. They designed a randomized clinical trial to determine 
whether systematic aortic and pelvic lymphadenectomy (n=216) could improve PFS and OS 
compared to the resection of bulky nodes alone (n=211). The median PFS was 29.4 and 22.4 
months (95% confidence interval [CI]=1.0–14.4 months, p=0.01) and the 5-year OS rates 
were 48.5% and 47% (hazard ratio [HR]=0.97, 95% CI=0.74–1.29, p=0.85) in the systematic 
lymphadenectomy and the control arms, respectively.
In 2019, Harter et al. [7] reported the results of the Lymphadenectomy in Ovarian 
Neoplasms (LION) trial in the New England Journal of Medicine. Based on their findings, 
systematic lymphadenectomy in patients with advanced ovarian cancer that lacked gross 
residual tumor and normal lymph nodes was not associated with improved PFS or OS 
relative to no lymphadenectomy. A total of 647 patients were assigned to either undergo 
(n=323) or not undergo (n=324) lymphadenectomy. Median PFS was 25.5 months in both 
groups (HR=1.11; 95% CI=0.92–1.34; p=0.29) while median OS was 69.2 months in women 
without lymphadenectomy and 65.5 months in women with lymphadenectomy (HR=1.06; 
95% CI=0.83–1.34; p=0.65). Infections treated with antibiotics, lymph cysts, and repeat 
laparotomies for complications were more common in women with lymphadenectomy. The 
authors assumed that the removal of these tumor cells could further reduce residual tumor 
burden to an extent that would improve prognosis. However, lymphadenectomy did not 
provide a survival benefit, despite the presence of positive nodes in 55.7% of patients in the 
lymphadenectomy group.
2. Secondary cytoreductive surgery in recurrent ovarian cancer
Recurrence occurs in almost all women with advanced ovarian cancer. Similar to primary 
surgical cytoreduction, secondary cytoreductive surgery could be considered for patients 
with recurrent disease. According to current guidelines from the National Comprehensive 
Cancer Network, secondary cytoreductive surgery is one of the treatment options for women 
with platinum-sensitive ovarian cancer [8]. However, based on the results of the Gynecologic 
Oncology Group (GOG)-213 trial, a phase 3 randomized prospective trial published by 
Coleman et al. [9], no survival benefits were obtained from secondary cytoreductive surgery 
followed by chemotherapy compared to chemotherapy alone in women with platinum-
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sensitive recurrent ovarian cancer. The median OS was 50.6 months in women with surgery 
and 64.7 months in women without surgery (HR=1.29; 95% CI=0.97–1.72; p=0.08) while 
median PFS was 18.9 months in women with surgery and 16.2 months in women without 
surgery (HR=0.82; 95% CI=0.66–1.01). Further, secondary cytoreductive surgery was not 
found to have an OS benefit over chemotherapy alone.
The DESKTOP-III trial (NCT01166737) was designed in a similar manner to the GOG-213 trial 
to evaluate the efficacy of secondary cytoreductive surgery; however, some differences exist 
between the 2 trials (Table 2) [10]. The DESKTOP-III trial comprised patients with complete 
gross resection after primary debulking surgery alone. This trial achieved complete gross 
resection in 68% of its study population, a finding similar to that of the GOG-213 trial which 
had 67% [11]. Although 84% of the study population received bevacizumab in GOG-213, only 
up to 20% of patients in DESKTOP-III received bevacizumab. Presently, we are awaiting the 
final results of the DESKTOP-III trial.
3. Dose-dense weekly paclitaxel scheduling
In the phase 3 ICON8 trial conducted by Gynecologic Cancer Intergroup and recently 
published in the Lancet, the first-line weekly dose-dense chemotherapy did not improve PFS 
compared to the thrice-weekly chemotherapy in women with stage IC–IV epithelial ovarian 
cancer [12]. The 1,566 eligible women were randomly assigned to the following three arms:
1)  carboplatin area under the curve (AUC) 5 or AUC 6 3-weekly + 175 mg/m2 paclitaxel 
3-weekly (group 1 [control arm], n=522)
2) carboplatin AUC 5 or AUC 6 3-weekly + 80 mg/m2 paclitaxel weekly (group 2, n=523)
3) carboplatin AUC 2 weekly + and 80 mg/m2 paclitaxel weekly (group 3, n=521)
There was no significant difference in PFS with either weekly regimen (median, 17.7 months; 
[interquartile range, 10.6-not reached] in group 1, 20.8 months [11.9–59.0] in group 2, 21.0 
months [12.0–54.0] in group 3; p=0.350 for group 2 vs. 1; p=0.510 for group 3 vs. 1). Grades 
3 or 4 toxic effects were frequent in women administered weekly treatment; however, most 
were uncomplicated.
Dose-dense weekly paclitaxel scheduling in epithelial ovarian cancer has already garnered 
remarkable attention in the past decade. The Japanese Gynecologic Oncology Group 
(JGOG)-3016 trial showed that dose-dense weekly paclitaxel-carboplatin improved survival 
outcomes in women with advanced epithelial ovarian cancer compared to the conventional 
thrice-weekly schedule [13]. A total of 637 Japanese women with newly diagnosed epithelial 
ovarian cancer were randomly assigned to receive 3 weekly doses of 180 mg/m2 paclitaxel 
with carboplatin or weekly dose-dense 80 mg/m2 paclitaxel with carboplatin thrice-weekly. 
Another randomized controlled trial, GOG-262, randomly assigned 692 women with stage 
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Table 2. Scheme of the DESKTOP-3 and GOG-213 trials
Variables DESKTOP-3 GOG-213
Design Randomized phase 3 trial Randomized phase 3, 1:1 trial
Primary endpoint Overall survival Overall survival
Enrolled patients (study period) 408 women (2010–2015) 485 women (2007–2017)
Patient selection Treatment-free interval >6 months, AGO score Treatment-free interval >6 months
Race/ethnicity 2% East-Asian 49.5% East-Asian
Complete resection 72.5% 67%
Bevacizumab in 2nd-line 20% 84%
HR for death (surgery vs. no surgery) Still blinded 1.29 (95% CI=0.97–1.72; p=0.08)
AGO, Arbeitsgemeinschaft Gynaekologische Onkologie; CI, confidence interval; HR, hazard ratio; GOG, Gynecologic Oncology Group.
II–IV epithelial ovarian cancer to receive 3-weekly 175 mg/m2 or weekly 80 mg/m2 paclitaxel 
treatment with carboplatin [14]. Unlike the JGOG-3016, 84% of participants in GOG-262 
received bevacizumab in addition to chemotherapy. No difference was observed in PFS 
between the 2 treatment groups; however, weekly paclitaxel improved PFS in the subgroup 
that did not receive bevacizumab.
In summary, weekly dose-dense paclitaxel chemotherapy cannot be generally recommended 
as a first-line regimen for women with epithelial ovarian cancer. However, it could be 
considered a first-line regimen option for Japanese women with ovarian cancer as potential 
ethnic differences might affect its pharmacological action.
4. Intraperitoneal (IP) therapy
Although reduced quality of life and increased toxicity are observed during IP treatment, 
intravenous (IV) paclitaxel with IP cisplatin and paclitaxel improved the PFS (23.8 vs. 18.3 
months, p=0.05) and OS (65.6 vs. 49.7 months, p=0.03) of women with optimally debulked 
stage III ovarian cancer compared to IV paclitaxel-cisplatin in the GOG-172 trial [15]. 
However, data from the recently published GOG-252 trial in the Journal of Clinical Oncology 
showed conflicting results [16]. When combined with bevacizumab, neither IP carboplatin 
nor cisplatin improved the outcomes of women with advanced ovarian cancer compared to 
IV carboplatin. A total of 1,560 women were enrolled and randomly assigned to the following 
three arms:
1)  IV paclitaxel 80 mg/m2 weekly + IV carboplatin (IV carboplatin group [control arm], 
n=521)
2) IV paclitaxel 80 mg/m2 weekly + IP carboplatin (IP carboplatin group, n=518)
3)  IV paclitaxel 135 mg/m2 3-weekly + IP cisplatin 75 mg/m2 day 2+ IP paclitaxel 60 mg/m2 
day 8 (IP cisplatin group, n=521)
All enrolled women received bevacizumab 15 mg/kg IV 3-weekly in cycles 2–22. The median 
PFS was 24.9 months, 27.4 months (HR=0.925; 95% CI=0.802–1.07), and 26.2 months 
(HR=0.977; 95% CI=0.847–1.13) while median OS was 75.5 months, 78.9 months (HR=0.949; 
95% CI=0.799–1.128), and 72.9 months (HR=1.05; 95% CI=0.799–1.128) in the IV carboplatin 
arm, IP carboplatin arm, and IP cisplatin arm, respectively. Grades 3 or 4 toxic effects were 
more common in the IP cisplatin arm; however, there was no increase in gastrointestinal 
perforations, fistulas, or necrosis in the IP cisplatin arm. The researchers suggested that IP 
therapy could remain an option for selected optimally debulked cases. Further, the regimen 
in the GOG-172 trial was recommended for use without bevacizumab.
5. Update on PARP inhibitors
First-line therapy
PARP inhibitors (niraparib, olaparib, and rucaparib) have been approved as maintenance 
therapy for patients with recurrent ovarian cancer who responded to platinum-based therapy 
and demonstrated efficacy according to their BRCA or homologous-recombination status 
(Table 3) [17-19]. Olaparib was approved as first-line maintenance therapy for the BRCAmut 
population based on promising results from the SOLO-1 trial [1].
Recently published first-line trials (Avastin and OLAparib in 1st Line [PAOLA-1], PRIMA, 
VELIA) [2,3,20] will completely change the management of ovarian cancer patients. 
Notably, however, major differences exist in trial designs, control arms, study populations 
(particularly sensitivity to prior platinum and residual disease), and timing of PARP inhibitor 
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initiation (concomitant with chemotherapy vs. maintenance only), ultimately rendering 
meaningful comparison impossible. The differences between the trials are evident when the 
control arms of the trials are compared, as they perform in a markedly different manner in 
different populations.
A study on the effects of niraparib as a first-line treatment was published in 2019 by 
González-Martín et al. [2]. These researchers presented the results of the randomized, 
double-blind phase 3 PRIMA trial, where benefits were observed with maintenance niraparib 
in patients with newly diagnosed ovarian cancer. Patients with high-risk ovarian cancer 
(International Federation of Gynaecology and Obstetrics [FIGO] III and IV), with response 
after frontline platinum therapy, were included despite their homologous-recombination 
deficiency (HRD) status. A total of 733 patients were randomized in a 2:1 ratio to receive 
niraparib or placebo for 36 months or until disease progression. In the overall population, a 
significantly longer PFS in the niraparib group (13.8 vs. 8.2 months, HR=0.62; p<0.001) and 
a higher gain in tumors with HRD, both BRCA-mutated and BRCA wild-type (21.9 months 
vs. 10.4 months, HR=0.43; p<0.001) were observed. OS at the 24-month analysis tended to 
increase OS in the niraparib group compared to the placebo group (84% vs 77%, HR=0.7; 
95% CI=0.44–1.11).
Promising results from VELIA/GOG-3005, a randomized phase 3 trial with veliparib 
combined with first-line chemotherapy and maintenance therapy, were published by 
Coleman et al. [3]. The trial comprised patients with stage III and IV ovarian cancer, 
regardless of BRCA or HRD status. A total of 1,140 patients were randomized (1:1:1) to receive 
chemotherapy plus veliparib followed by either veliparib (veliparib throughout) or placebo 
maintenance or control with chemotherapy plus placebo followed by placebo maintenance. 
The regimen of carboplatin, paclitaxel, and veliparib (6 cycles) followed by 30 cycles of 
maintenance veliparib led to a significantly longer PFS in the intention-to-treat population. 
Median PFS in the intention-to-treat cohort was 23.5 vs. 17.3 months in the control group 
(HR=0.68; p<0.001). A higher benefit was observed in the BRCA mutation cohort (34.7 vs 
22.0 months, HR=0.44; p<0.001) and the HRD cohort, including BRCAmut (31.9 vs. 20.5 
months, HR=0.57; p<0.001). In the veliparib concomitant only group, no benefits were 
observed for the improved PFS. At the time of publication, data regarding OS were not 
mature. Regarding safety, most adverse advents were reported in the veliparib throughout 
group, which had higher incidence of thrombocytopenia, anemia, and nausea.
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Table 3. Summary of clinical trials for PARP inhibitors
Variables PARP inhibitor PARP inhibitor+VEGF inhibitor PARP inhibitor+ICI PARP inhibitor+ICI+VEGF inhibitor
First-line maintenance SOLO-1 (olaparib) PAOLA-1 (olaparib+bev) ATHENA (rucaparib+nivolumab)†
PRIMA (niraparib) MITO-25 (rucaparib+bev)†
First-line treatment & 
maintenance










SOLO-3 (olaparib) AVANOVA-2 (niraparib+bev) MEDIOLA (olaparib+durvalumab)* MEDIOLA (olaparib+durvalumab+bev)†,‡
QUADRA (niraparib) NRG GY-004 (olaparib+cediranib)†
Recurrence treatment, 
platinum resistant
NRG GY-005 (olaparib+cediranib)† TOPACIO (niraparib+pembrolizumab)
bev, bevacizumab; ICI, immune checkpoint inhibitor; PARP, poly(ADP-ribose) polymerase; VEGF, vascular endothelial growth factor.
*Abstract only; †Ongoing study; ‡Expansion cohort.
Recurrent ovarian cancer
Del Campo et al. published data regarding the efficacy of niraparib maintenance therapy 
in patients with recurrent ovarian cancer based on the best response to the final platinum-
based chemotherapy [21]. Data were evaluated based on the results from the ENGOT-OV16/
NOVA trial [17], a double-blind, randomized study of 553 patients with recurrent, platinum-
sensitive ovarian cancer. Patients from the niraparib group achieved clinical benefit, with a 
significantly longer PFS than those in the placebo group, regardless of complete response 
(CR) or partial response (PR) to their last platinum-based therapy in the BRCA mutation 
cohort (CR: HR=0.3; p<0.0001 and PR: HR=0.24; p<0.0001) and non-BRCA mutation cohort 
(CR: HR=0.58; p=0.0082 and PR: HR=0.35; p<0.0001). The status and reports of severe 
symptoms were low in all groups.
Matulonis et al. [22] reported time without symptoms and toxicity (TWiST) in patients from 
the same ENGOT-OV16/NOVA trial. TWiST was estimated to be the difference between the 
mean PFS and time with toxicity or symptoms (number of days with symptomatic grade ≥2 
between randomization and progression). Compared to those administered placebo, patients 
administered niraparib experienced a benefit of 2.95 years without toxicity or symptoms 
in the BRCA mutation cohort and 1.34 years in the non-BRCA mutation cohort, ultimately 
depicting the potential of patients to experience a better quality of life.
The effect of age on the efficacy and safety of rucaparib maintenance treatment was previously 
investigated. Ledermann et al. analyzed data from three age-based subgroups from ARIEL3 
where patients were randomized to receive either rucaparib or placebo [23]. Maintenance 
with rucaparib was demonstrated to improve PFS in all age subgroups compared to placebo; 
however, the highest benefit was observed in patients <65 years with median PFS of 11.1 vs 
5.4 months in the control group (HR=0.33; 95% CI=0.25–0.43). Patients aged 65–74 and ≥75 
had had a longer PFS of 3 and 3.7 months, respectively, than those in the control group. In 
addition, the safety profile was consistent across the subgroups.
Late-line therapy
The QUADRA trial evaluated the safety and efficacy of niraparib monotherapy as a late-line 
treatment for high-grade ovarian cancer [24]. In this open-label, single-arm phase 2 trial, 
patients were administered more than three previous chemotherapy regimens, regardless 
of their HRD status and platinum status (sensitive, resistant or refractory). Further, they 
received daily niraparib until disease progression. The primary endpoint was to evaluate the 
efficacy of niraparib on HRD-positive tumors that are sensitive to the final platinum-based 
therapy. A total of 463 patients were enrolled: 47 patients met the primary endpoint and 28% 
(13/47) achieved overall response (95% CI=15.6–42.6; p=0.00053). The median duration of 
response was 9.2 months, and 68% (37/47) of patients achieved disease control. The overall 
response rate was 10% (38 of 387 response-evaluable) and was highest in patients with BRCA-
mutated and HRD-positive tumors. No new safety signals were identified.
Dose and tolerability
Previous analysis from the NOVA phase 3 trial revealed a platelet count <150,000/µL and 
body weight <77 kg as predictive factors for the poor tolerability of niraparib. Based on 
these findings, a reduction of the starting-dose to 200 mg was recommended for this group 
of patients [17]. Data from the PRIMA trial were presented at the Society of Gynecologic 
Oncology annual meeting 2019 [25]. The results of this trial prospectively confirmed that 
niraparib tolerability was improved when dosing was derived according to body weight (<77 
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kg) and platelet count (150,000/µL). A post hoc analysis of the phase 2 QUADRA trial also 
showed that patients with either lower body weight or platelet count experienced more ≥3 
grade toxicity. Further, efficacy was preserved in the group administered a reduced daily 
mean dose (≤200 mg) of niraparib [26].
Combination therapy with a PARP inhibitor and vascular endothelial growth factor inhibitor
The combination of a PARP inhibitor and an anti-angiogenic agent as maintenance therapy 
has demonstrated efficacy with improved PFS in patients with recurrent ovarian cancer 
[27,28]. The efficacy and safety of the more intensive first-line maintenance regimen of 
olaparib plus bevacizumab were investigated in the PAOLA-1/ENGOT-ov25 trial and published 
in December 2019 by Ray-Coquard et al [20]. This trial was a randomized, double-blind 
study of patients that were newly diagnosed with FIGO stage III and IV ovarian cancer that 
responded to platinum-based therapy plus bevacizumab irrespective of their BRCA mutation 
status. A total of 806 patients were randomized (2:1) to receive olaparib plus bevacizumab or 
placebo plus bevacizumab. Median PFS was 22.1 months in the olaparib group and 16.6 in 
the placebo group (HR=0.59; 95% CI 0.49–0.72; p<0.001). Further, the longest duration was 
observed in the BRCA-mutated and HRD-positive tumors. Grades 3–5 adverse events were 
reported by 57% of patients in the olaparib group and 51% in the placebo group. The most 
common events were hypertension and anemia.
Positive results were published by Mirza et al. [29] regarding niraparib and bevacizumab 
for the treatment of recurrent ovarian cancer. The NSGO-AVANOVA2/ENGOT-OV24 phase 
2 superiority trial compared niraparib monotherapy to niraparib plus bevacizumab. A total 
of 97 patients with platinum-sensitive recurrent ovarian cancer, regardless of the number 
of previous lines of therapy and HRD status, were randomized in a 1:1 ratio. Combination 
treatment was found to significantly increase PFS compared to niraparib monotherapy, with 
a median PFS of 11.9 vs. 5.5 months (HR=0.35; p<0.001). Further, a significant benefit was 
observed despite the HRD status or a chemo-free interval greater or less than 12 months. The 
proportion of patients with objective response was higher with combination therapy (62%) 
than monotherapy (30%). More grade ≥3 events were registered in the combination group 
owing to more frequent hypertension.
Combination therapy with a PARP inhibitor and immunotherapy
Konstantinopoulos et al. [30] published the results from the ovarian cohort of the Niraparib 
in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or 
Ovarian Cancer (TOPACIO; NCT02657889)/KEYNOTE-162 trial, a single-arm phase 1 and 2 
trial with niraparib combined with pembrolizumab for patients with recurrent ovarian cancer, 
regardless of their BRCA status. A total of 62 patients were included in the study (9 in phase 1 
and 53 in phase 2). Interestingly, 3 patients (5%) had confirmed CR, 8 patients (13%) had PR, 
and 28 patients (47%) had stable disease. Moreover, the objective response was consistent 
across the subgroups based on platinum sensitivity status, BRCA status, or HRD status. The 
median duration of response was not reached (range, 4.2 to ≥14.5 months) and no new safety 
signals were identified.
Combination therapy with a PARP inhibitor and a phosphoinositide 3-kinase (PI3K) inhibitor
To date, every trial that explored the combination of PARP inhibitors with targeted 
agents, such as cediranib and buparlisib, failed to demonstrate their clinical synergism in 
homologous-recombination repair (HRR)-proficient ovarian cancer. Konstantinopoulos et 
al. [31] were the first to present clinical evidence of synergism between PARP inhibitor and a 
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targeted agent in BRCA wild-type, platinum-resistant ovarian cancer through a multicenter, 
open-label, phase 1b trial. Of the 28 patients with epithelial ovarian cancer, the overall 
response was 33% (95% CI 7-70) in patients with germline BRCA mutations and platinum-
resistant or refractory disease. As the overall response rate was substantially higher than 
that expected from olaparib monotherapy (4%–5%) or alpelisib monotherapy (<5%) in this 
setting, clinical synergism was suggested. Plausible mechanisms of the clinical synergism 
include the use of a PI3K inhibitor to sensitize HRR-proficient ovarian cancers to PARP 
inhibitors, which suggest the potential use of PARP inhibitors beyond the HRR-deficient 
setting. The most common grade 3–4 adverse events were hyperglycemia (16%), nausea (9%), 
and increased alanine aminotransferase concentrations (9%).
UTERINE CORPUS
1. Adjuvant therapy in high-risk endometrial cancer
The preventive role of radiotherapy in locoregional recurrent endometrial cancer has been 
well established; however, external-beam radiotherapy (EBRT) does not significantly improve 
OS in women with early-stage or low-risk endometrial cancer [32,33]. Based on distant 
metastasis, chemotherapy is considered to be the standard of care; however, the role of 
radiotherapy remains controversial [34].
GOG-258: chemoradiation vs. chemotherapy alone in stage III–IVA endometrial cancer
Last year, the Randomized Trial of Radiation Therapy With or Without Chemotherapy 
for Endometrial Cancer (PORTEC-3; NCT00411138) trial demonstrated that adjuvant 
chemoradiotherapy improved the PFS in women with stage III endometrial cancer relative to 
radiotherapy alone [35]. Based on the data from the phase 3 GOG-258 trial, Matei et al. [36] 
demonstrated that chemoradiotherapy did not improve relapse-free survival (RFS) relative 
to chemotherapy alone in women with high-risk endometrial cancer [36]. A total of 736 
eligible women with stage III–IV of any histologic type or stage I–II non-endometrioid type 
endometrial cancers, were randomly assigned (1:1) to receive adjuvant chemoradiotherapy 
or chemotherapy only after surgery. The chemoradiotherapy group received 50 mg/m2 
cisplatin on days 1 and 29 with EBRT followed by 175 mg/m2 paclitaxel plus carboplatin at 
AUC 5 to 6 thrice-weekly for 4 cycles. The chemotherapy only group received 175 mg/m2 
paclitaxel plus carboplatin at AUC 5 to 6 thrice-weekly for 6 cycles. As a result, the 5-year 
RFS was 59% in women administered chemoradiotherapy and 58% in those administered 
chemotherapy alone (HR=0.90; 90% CI=0.74–1.10). Although the recurrence of vaginal (2% 
vs. 7%, HR=0.36, 95% CI=0.14–0.82) and lymph node (11% vs. 20%, HR=0.43; 95% CI=0.28–
0.66) was less frequent in women administered chemoradiotherapy, distant recurrence 
(27% vs. 21%, HR =1.36; 95% CI=1.00–1.86) was more common in women treated with 
chemoradiotherapy. Grade 3 or 4 toxic effects occurred in 58% of the chemoradiotherapy 
group and 63% of the chemotherapy only group.
GOG-249: pelvic radiotherapy vs. brachytherapy plus chemotherapy in high-intermediate 
and high-risk early-stage endometrial cancer
In another GOG study, an open-label phase 3 trial, the potential to replace adjuvant pelvic 
radiotherapy with vaginal cuff brachytherapy with chemotherapy (VAB-C) was determined 
in women with high-risk early-stage (grade 2 or 3, positive LVSI, IB–II endometrioid, I–II 
serous or clear cell) endometrial cancer [37]. In this trial, VCB-C was not superior to pelvic 
radiotherapy based on the survival outcomes and toxicities. A total of 601 women were 
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randomly assigned (1:1) to receive VAB-C or pelvic radiotherapy. Pelvic radiotherapy was 
performed with the standard 4-field techniques or intensity-modulated radiotherapy. The 
pelvic radiotherapy dose was 45–50.4 Gy over 5–6 weeks. Women with VCB-C concomitantly 
received brachytherapy and chemotherapy comprising of 175 mg/m2 paclitaxel and 
carboplatin thrice-weekly. The 5-year RFS was 0.76 (95% CI=0.70–0.81) for radiotherapy and 
0.76 (95% CI=0.70–0.81) for VCB-C (HR=0.92; 90% confidence limit=0.69–1.23). Further, 
the 5-year OS was 0.87 (95% CI=0.83–0.91) for radiotherapy and 0.85 (95% CI=0.81–0.90) 
for VCB-C (HR=1.04; 90% confidence limit=0.71 –1.52). Although the incidence of vaginal 
or distant recurrences did not differ, pelvic or para-aortic lymph node recurrences were 
less frequent in women with radiotherapy (HR=0.42; 95% CI=0.24–0.94). The researchers 
mentioned that pelvic radiotherapy is adequately managed in women with high-risk early-
stage endometrial cancer.
2. Chemotherapy for high-risk endometrial cancer
JGOG-2043: doxorubicin plus cisplatin vs. docetaxel plus cisplatin vs. paclitaxel plus 
carboplatin
According to the results of GOG-122, doxorubicin-cisplatin can be recommended for use 
as the standard regimen for adjuvant chemotherapy in advanced and recurrent endometrial 
cancers [11]. Additionally, taxanes such as paclitaxel and docetaxel were reported to 
be effective [34,38]. In JAMA Oncology, Nomura et al. [39] demonstrated that women 
administered doxorubicin-cisplatin, docetaxel-cisplatin, or paclitaxel-carboplatin as adjuvant 
chemotherapy after surgery for endometrial cancer had similar oncologic outcomes. In 
this multicenter, open-label, phase 3 randomized clinical trial, 788 women with stage I–II 
endometrial cancer at high-risk or stage III–IVA were enrolled and randomly assigned (1:1:1) 
to receive 60 mg/m2 doxorubicin plus 50 mg/m2 cisplatin, 70 mg/m2 docetaxel plus 60 mg/m2 
cisplatin, and 180 mg/m2 paclitaxel plus carboplatin AUC 6, respectively. The 5-year PFS was 
73.3%, 79.0%, and 73.9% in women administered doxorubicin-cisplatin, docetaxel-cisplatin, 
or paclitaxel-carboplatin, respectively (2-sided p=0.12). Further, the 5-year OS was 82.7%, 
88.1%, and 86.1% in women administered doxorubicin-cisplatin, docetaxel-cisplatin, or 
paclitaxel-carboplatin, with no significant differences observed (2-sided p=0.37). Although 
the superiority of docetaxel-cisplatin and paclitaxel-carboplatin over doxorubicin-cisplatin 
was not demonstrated, the authors suggested that the 3 regimens are comparable in efficacy 
and tolerability.
GOG-261: paclitaxel plus carboplatin vs. paclitaxel plus ifosfamide
The results from the phase 3 NRG Oncology clinical trial, GOG-261, were reported at the 
2019 ASCO Annual Meeting. Based on the results, paclitaxel-carboplatin was not inferior to 
paclitaxel-ifosfamide in the survival outcomes [40]. A total of 449 women with chemotherapy 
naïve stage I-IVB or recurrent uterine carcinosarcoma were enrolled and randomly assigned 
(1:1) to receive 175 mg/m2 paclitaxel plus carboplatin AUC 5–6 or 135 mg/m2 paclitaxel plus 
1.6 g/m2 ifosfamide on days 1–3. Median OS (37 vs. 29 months, HR=0.87; 90% CI=0.70–1.075; 
p<0.01 for non-inferiority [NI], p>0.1 for superiority [S]) was not inferior; however, PFS (16 
vs. 12 months, HR=0.73; p<0.01 for NI, p<0.01 for S) was longer in women administered 
paclitaxel-carboplatin than those administered paclitaxel-ifosfamide. Most toxic events in 
women with paclitaxel-carboplatin were hematologic complications, and confusion and 
genitourinary hemorrhage were worse in women administered paclitaxel-ifosfamide.
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RADIATION ONCOLOGY
1.  Inferiority of neoadjuvant chemotherapy (NAC) plus chemoradiotherapy 
(CRT) to CRT alone
A randomized phase II study conducted by da Costa et al. [41] and published online in the 
Journal of Clinical Oncology showed that combination therapy with gemcitabine and cisplatin 
followed by CRT did not improve the outcomes of patients with locally advanced cervical 
cancer compared to CRT alone. Of the 107 patients enrolled in the study, 55 and 52 were 
randomly assigned to the NAC arm and CRT-alone arm, respectively. Most patients were 
found to have squamous cell carcinoma (87.8%). Further, the primary end point was 3-year 
PFS while the secondary end points were response rate, 3-year locoregional control, 3-year 
OS, safety, and quality of life. After a median follow-up of 31.7 months, NAC was associated 
with an inferior PFS, with 3-year PFS rates of 40.9% vs. 60.4% in the CRT arm (HR=1.84; 
95% CI=1.04–3.26; p=0.033). Additionally, NAC was associated with a lower OS (3-year OS 
rate, 60.7% vs. 86.8%, HR=2.79; 95% CI=1.29–6.01; p=0.006). After treatment completion, 
CR rates were 56.3% in the NAC arm and 80.3% in the CRT arm (p=0.008). Toxicities were 
similar in both arms, with the exception of hypomagnesemia and neuropathy, which were 
more common with NAC.
2. Treatment of radiation-induced cystitis using hyperbaric oxygen
Late radiation cystitis often occurs in 23% to 80% of patients while severe hematuria is 
reported to occur in 5% to 8% of patients with prostate, rectal, or gynecologic cancers [42]. 
Symptoms of late radiation cystitis include hematuria, increased urinary frequency and 
urgency, incontinence, and dysuria. Hyperbaric oxygen therapy (HBOT) was suggested to 
relieve the symptoms caused by radiotherapy; however, only little evidence regarding the use 
of HBOT is available as small sized randomized studies have failed to demonstrate its benefit.
The first study published online on September 16, ahead of print, in Lancet Oncology revealed 
that HBO can alleviate symptoms of late radiation cystitis in patients that underwent 
pelvic radiotherapy [43]. Oscarsson et al. [43] conducted a randomized, controlled phase 
II–III study with HBOT in patients with radiation-induced cystitis. Of the 223 patients 
screened between May 9, 2012, and Dec 20, 2017, 87 were enrolled and randomly assigned 
to receive either hyperbaric oxygen therapy (n=42) or standard care (n=45). The intent-to-
treat population included 79 patients (41 in HBOT, 38 in standard care) with symptoms of 
late radiation cystitis. Most patients had prostate cancer (68%) followed by cervical cancer 
(23%). The median time from radiotherapy to inclusion in the study was over 4 years for both 
groups. The primary outcome was the urinary total score based on the Expanded Prostate 
Cancer Index Composite (EPIC) score. Significantly better improvements were observed with 
HBOT for the bother and incontinence EPIC scores and the bowel EPIC scores. The difference 
between the change in the group mean of the urinary total EPIC score at visit 4 was 10.1 
points (95% CI=2.2–18.1; p=0.013, 17.8 points [standard deviation=18.4] in the HBOT group 
vs. 7.7 points [15.5] in the standard care group). Of the 41 patients in the HBOT group, 17 
(41%) experienced transient grade 1–2 adverse events, related to sight and hearing, during the 
period of hyperbaric oxygen therapy. SF-36 scores had better improvements with HBOT than 
standard care, especially a significant improvement in general health (p=0.0006).
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BREAST
1. Humanized monoclonal antibodies in breast cancer
Trastuzumab emtansine for residual invasive human epidermal growth factor receptor 2 
(HER2)-positive breast cancer
Drug treatments for HER2-positive breast cancer have enabled a remarkable success story, and 
trastuzumab emtansine (T-DM1), an antibody-drug conjugate, has demonstrated remarkable 
activity against metastatic breast cancer after progression with the use of trastuzumab. 
Neoadjuvant chemotherapy before definitive surgery is an established treatment approach for 
operable breast cancer. Further, patients with residual invasive disease at surgery following 
neoadjuvant therapy have a higher risk of disease recurrence or death than patients with a 
pathological CR.
A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients 
With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary 
Lymph Nodes Following Preoperative Therapy (KATHERINE; NCT01772472) is a phase 
3, open-label trial comprising of patients with HER2-positive early breast cancer with a 
residual invasive disease in the breast or axilla at surgery post-treatment with a neoadjuvant 
containing a taxane and trastuzumab [44]. Patients were randomly assigned to receive 
adjuvant T-DM1 or trastuzumab, which is the current standard of treatment, for 14 cycles. 
Among the 1,486 randomly assigned patients, invasive disease or death occurred in 91 
patients in the T-DM1 group (12.2%) and 165 patients in the trastuzumab group (22.2%). 
Invasive disease-free survival was significantly higher in the T-DM1 group than the 
trastuzumab group (HR=0.50; 95% CI=0.39–0.64; p<0.001). The safety data were consistent 
with the known safety profile of T-DM1, with more adverse events being associated with 
T-DM1 than trastuzumab alone.
These results are clinically meaningful and could be used to establish a new standard of care 
for patients with residual disease after neoadjuvant therapy.
Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer
Sacituzumab govitecan-hziy is an antibody–drug conjugate against human trophoblast cell-
surface antigen 2 (Trop-2), with SN-38, a cytotoxic warhead. Sacituzumab govitecan-hziy 
enables the delivery of high concentrations of SN-38 to tumors.
In a phase 1/2 single-group, multicenter trial involving 108 patients with triple-negative 
breast cancers and intravenously administered 10 mg/kg of sacituzumab govitecan-hziy 
on days 1 and 8 of each 21-day cycle, the response rate (3 CR and 33 PR) was 33.3% (95% 
CI=24.6–43.1) and the median duration of response was 7.7 months (95% CI=4.9–10.8) [45]. 
Four deaths occurred during treatment and 3 patients (2.8%) discontinued treatment due to 
adverse events. The grades 3 or 4 adverse events (in ≥10% of the patients) were anemia and 
neutropenia and 10 patients (9.3%) had febrile neutropenia.
As patients were heavily pretreated with a median of 3 previous therapies (range, 2 to 10), 
where standard chemotherapy is associated with low response rates (10% to 15%) and short 
PFS (2 to 3 months), the high response rate is remarkable and warrants further evaluation in 
future phase III trials.
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2. Combination therapy in breast cancer
Alpelisib for PIK3CA-mutated, hormone receptor–positive advanced breast cancer
More than 70% of breast cancer cases are hormone receptor (HR)–positive and HER2–
negative, and approximately 40% of these patients have activating mutations in the PIK3CA 
gene, which results in the hyperactivation of the α isoform of PI3K. Alpelisib is an orally 
bioavailable, small-molecule, α-specific inhibitor of PI3K.
SOLAR-1 is a randomized, double-blind, placebo-controlled, phase 3 trial of fulvestrant plus 
alpesilib or placebo in patients with HR-positive, HER2-negative advanced breast cancer who 
had previously received endocrine therapy [46]. Patients were categorized into two cohorts 
according to their tumor-tissue PIK3CA mutation status (PIK3CA-mutated vs. not PIK3CA-
mutated). The primary end point was PFS, as assessed by the investigator, in the cohort with 
PIK3CA-mutated cancer.
A total of 572 patients underwent randomization, including 341 patients with confirmed 
tumor-tissue PIK3CA mutations. In the cohort of patients with PIK3CA-mutated cancer, 
PFS at the median follow-up of 20 months was 11.0 months (95% CI=7.5–14.5) in the 
alpelisib–fulvestrant group and 5.7 months (95% CI=3.7–7.4) in the placebo-fulvestrant group 
(HR=0.65; 95% CI=0.50–0.85; p<0.001). In the cohort without PIK3CA-mutated cancer, 
the hazard ratio was 0.85 (95% CI=0.58–1.25). Further, the response rate was higher in the 
combination group in the PIK3CA-mutated cohort (26.6% vs. 12.8%). The most frequent 
grade 3 or 4 adverse events were hyperglycemia (36.6% in the alpelisib–fulvestrant group vs. 
0.7% in the placebo–fulvestrant group), rash (9.9% vs. 0.3%), and diarrhea (6.7% vs. 0.3%).
The efficacy and safety profiles of alpelisib were found to be better than those of other PI3K 
inhibitors whose development was discontinued. Further, its clinical utility could be determined.
OS with fulvestrant plus anastrozole in metastatic breast cancer
In a previous report (S0226 study), the combination of anastrozole, an aromatase inhibitor, 
with fulvestrant, a selective estrogen-receptor down-regulator, was demonstrated to prolong 
PFS and marginally prolong OS relative to anastrozole alone [47]. The final results regarding 
OS was reported this year [48].
Of the 707 patients who had undergone randomization, 694 had data available for analysis. 
The combination therapy group had a median OS of 49.8 months relative to the 42.0 months 
observed in the anastrozole-alone group (HR for death=0.82; 95% CI=0.69–0.98; p=0.03). 
In a subgroup analysis, OS among women who did not previously receive tamoxifen was 
longer with the combination therapy than anastrozole alone (median, 52.2 and 40.3 months; 
HR=0.73; 95% CI=0.58–0.92); among women that had previously received tamoxifen, OS was 
similar between the 2 groups (median, 48.2 and 43.5 months; HR=0.97; 95% CI=0.74–1.27) 
(p=0.09 for interaction).
Conversely, other trials (FACT2 and SoFEA3) [49,50] revealed that the combination of an 
aromatase inhibitor and fulvestrant was not superior to the aromatase inhibitor alone. This 
could be observed in the patient population included in the S0226 study, where most patients 
did not have any prior exposure to endocrine therapy and might have been more sensitive to 
endocrine treatment.
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OS with ribociclib plus endocrine therapy in breast cancer
Although young age at the diagnosis of breast cancer has been associated with worse 
outcomes and less sensitivity to endocrine therapy, data on young premenopausal or 
perimenopausal women have been limited. In a previous report, ribociclib, a CDK4/6 
inhibitor, combined with endocrine therapy (goserelin and letrozole or tamoxifen) was 
reported to improve PFS relative to endocrine therapy alone [51]. The updated OS, which was 
the key secondary endpoint, was reported this year [52].
The addition of ribociclib to endocrine therapy resulted in a significantly longer OS than 
treatment with endocrine therapy alone. In fact, the estimated OS at 42 months was 70.2% 
(95% CI=63.5–76.0) in the ribociclib group and 46.0% (95% CI=32.0–58.9) in the placebo group 
(HR=0.71; 95% CI=0.54–0.95; p=0.00973). The survival benefit observed in the subgroup 
containing 495 patients administered an aromatase inhibitor was consistent with that observed 
in the overall intention-to-treat population (HR for death=0.70; 95% CI=0.50–0.98).
These results validate the use of the CDK4/6 inhibitor combined with endocrine therapy 
as the first-line standard of care, even for premenopausal patients. The findings presented 
herein could also contribute to future trial designs for premenopausal or perimenopausal 
patients with breast cancer.
CONCLUSION
Today, more effort, time, and money are required before the safety and effectiveness of 
therapies can be investigated in clinical trials. Despite the need for more studies, many 
researchers are dedicated to improving the health of women worldwide. As a result, we 
anticipate the publication of pioneering research in the future.
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